Latest filing published 24 Jan 2022 for InMed Pharmaceuticals Inc., €3,817.
Filing timeline
BuySaleInsider track record
Bruce Colwill: trading record in brief
Bruce Colwill discloses dealings in InMed Pharmaceuticals Inc. to SEC (Form 4). Between 9 October 2019 and 24 January 2022, the trades on record add up to 5 filings.
Purchases make up the whole of the open-market record (5 purchases, €13k). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2022, the count stands at 1 purchase and no sales.
A typical purchase (the median) is worth €1,829. No cluster: in 5 purchases, no other insider of the company bought within 30 days.
The newest entry dates from 24 January 2022: an open-market purchase of €3,817, in InMed Pharmaceuticals Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Bruce Colwill
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,000 shares@ CA$1.087728.4% of flowCommon SharesTSXSEDI:3874302Canonical exit: 24 Apr 2022 (T+90)
- 5,000 shares@ CA$1.76862.1% of flowCommon SharesTSXSEDI:3809397Canonical exit: 27 Dec 2021 (T+90)
- 5,000 shares@ CA$0.279.7% of flowCommon SharesTSXSEDI:3441785Canonical exit: 22 Jan 2020 (T+90)
- 5,000 shares@ CA$0.2589.2% of flowCommon SharesTSXSEDI:3438360Canonical exit: 9 Jan 2020 (T+90)
- 10,000 shares@ CA$0.26819.0% of flowCommon SharesTSXSEDI:3438355Canonical exit: 7 Jan 2020 (T+90)
5 of 5 declarations
